Alliances

Found 54,227 articles

• Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

  4/25/2023

  Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI) today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.

• InfuSystem Announces Distribution Agreement with Genadyne for Negative Pressure Wound Therapy Systems

  4/25/2023

  InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today a national distribution agreement with Genadyne Biotechnologies Inc. for its negative pressure wound therapy (“NPWT”) systems and supplies.

• ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

  4/25/2023

  ALX Oncology Holdings Inc. today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA.

• CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine(R)

  4/25/2023

  CANAQUEST MEDICAL CORP. (OTC PINK:CANQF) (the "Company" or "CanaQuest") today announced the signing of a Master Service Agreement with Neeka Health ("Neeka") that will encompass multiple clinical studies to evaluate the efficacy of Mentanine® on targeted populations struggling with transitional issues.

• Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

  4/25/2023

  Alkermes plc  (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V.

• CLS Americas and Unio Health Partners Announce Clinical Study “Micro Ultra-Sound Guided Focal Laser Ablation of Low to Intermediate Risk Prostate Cancer”

  4/25/2023

  Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has entered into an agreement with Unio Health Partners (formerly Genesis Research), to conduct a Phase I clinical study titled, “Micro Ultra-Sound Guided, Transperineal Focal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”

• Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S.

  4/25/2023

  Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company") today announced that it has signed a new three-year agreement with Boston IVF, a pioneer in reproductive healthcare and innovative research and one of the world's most experienced fertility treatment providers.

• Asensus Surgical Announces Fukuoka Tokushukai Hospital in Japan to Initiate Senhance Surgery Program

  4/25/2023

  Asensus Surgical, Inc. today announced that Fukuoka Tokushukai Hospital in Kasuga City, Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.

• American Urological Association Releases Non-Metastatic Upper Tract Urothelial Carcinoma Guideline

  4/25/2023

  Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2023 clinical practice guideline for the diagnosis and management of non-metastatic upper tract urothelial carcinoma (UTUC).

• Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™

  4/24/2023

  Cidara Therapeutics, Inc. today announced receipt of a $20 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYO™ (rezafungin for injection), a novel, once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis.

• Bacthera Joins Microbiome Therapeutics Innovation Group

  4/24/2023

  The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bacthera to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.

• Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

  4/24/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced a partnership with the Colorectal Cancer Alliance, the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase awareness and access to preventative colorectal screenings in medically underserved communities.

• Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

  4/24/2023

  Aevitas Therapeutics, Inc. today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.

• Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting

  4/24/2023

  –– Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health journeys of patients with neurologic diseases.

• Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

  4/24/2023

  Lantheus Holdings, Inc. and POINT Biopharma Global, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC).

• Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks

  4/24/2023

  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis' eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.

• Visolis and Ginkgo Bioworks Announce Partnership to Improve Microbial Strain for Bio-Isoprene and Sustainable Aviation Fuel Production

  4/24/2023

  Visolis today announced a partnership with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity.

• Bayer Announces New Strategic Collaboration with New Jersey’s Leading Polytechnic Universities to Cultivate Data Science Talent in Region

  4/24/2023

  Today the Consumer Health North America division of Bayer announced a new strategic collaboration with two of New Jersey’s leading polytechnic universities – New Jersey Institute of Technology (NJIT) and Stevens Institute of Technology (Stevens).

• PicnicHealth Announces Continued Real-World Data Strategic Partnership with Roche and Genentech to Advance Neurological Disease Research

  4/24/2023

  PicnicHealth, a patient-centered health technology company, announced its intent to globally expand its partnership with Roche and Genentech to accelerate neurological disease research through investments in real-world data.

• NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

  4/24/2023

  Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.